222 Mason St
San Francisco, CA, 94102
Saturday, April 27, 2024
AAIFNC 2024 Annual Symposium: Bridges to Understanding
Activity Date & Location
Saturday, April 27, 2024
Hotel Nikko, San Francisco
At the end of this activity, participants should be able to:
- Review current and future treatments in the management of food allergies.
- Understand how epigenetic mechanisms may influence the pathophysiological processes in asthma.
- Evaluate strategies for treatment of chronic rhinosinusitis with nasal polyposis.
- Review and understand treatment considerations for patients with hereditary angioedema.
- Describe the efficacy, safety, and clinical decision-making for initiating and continuing venom immunotherapy.
- Review diagnostic and treatment regimens for drug allergies.
- Describe the pathophysiology of sleep disorders and their effects on the upper airway.
- Understand clinical considerations in managing asthma in pregnancy.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology and The Allergy, Asthma & Immunology Foundation of Northern California (AAIFNC). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
In compliance with the Americans with Disabilities Act, ACAAI requests that participants in need of special accommodation submit a written request well in advance. Please contact Karol Anderson at firstname.lastname@example.org.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 7 contact hours.
Practicing allergists and allied health care providers in the field of allergy and immunology.
Jointly Provided by the American College of Allergy, Asthma & Immunology and the Allergy, Asthma & Immunology Foundation of Northern California.
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Examples of such organizations include advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers.
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.
Industry-led lectures and exhibits will be conducted as optional learning opportunities in conjunction with this event. These optional activities are not certified for CME credit and are not planned or sanctioned by the American College of Allergy, Asthma and Immunology or AAIFNC.
The committee includes the following: Gregory Bensch MD, A.Carmen Choy MD, Javaid M. Khan, DO, Steve Machtinger MD, Sean McGhee MD PhD, Iris Otani MD, Sarah Pederson RN, Kristina H.Philpott MD, Dai Park MD, Michelle Huffaker MD, Karol Anderson
In compliance with the Americans with Disabilities Act, AAIFNC requests that any participant in need of accommodation send email to: email@example.com